Approximately 70% of patients with advanced breast cancer (ABC) have hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐negative (HR+/HER2−) disease and are commonly treated with endocrine‐based therapies [1, 2, 3]. This evidence concerns the gene ERBB2 and breast carcinoma.